

Anti-Siglec-8 Antibody (Lirentelimab)

Introduction

Lirentelimab (AK002) is a humanized IgG1 Monoclonal antibody targeting sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab-induced IL-5 Activated eosinophils Apoptosis and inhibit IL-5 Mediated mast cell activation. Lirentelimab can be used in the study of eosinophilic gastritis and duodenitis.

Product parameters

Alternative Names	AK 002, Lirentelimab, AK-002
Target Accession	Q9NYZ4
Target	Siglec-8
CAS number	2283348-97-8
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

